ORIGINAL RESEARCH

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA

Kristin Schmiedeberg,1 Irene A Abela,2,3 Natalia Barbara Pikor,4 Nicolas Vuilleumier,5 Magdalena Schwarzmüller,2,3 Selina Epp,2,3 Sabrina Pagano,5 Sarah Grabherr,4 Angelica Brooke Patterson,4 Madalina Nussberger,1 Alexandra Trkola,2,3 Burkhard Ludewig,4,6 Johannes von Kempis,1 Andrea Rubbert-Roth 1

ABSTRACT

Objectives To correlate immune responses following a two-dose regimen of mRNA anti-SARS-CoV-2 vaccines in patients with rheumatoid arthritis (RA) to the development of a potent neutralising antiviral activity.

Methods The RECOVER study was a prospective, monocentric study including patients with RA and healthy controls (HCs). Assessments were performed before, and 3, 6, 12 and 24 weeks, after the first vaccine dose, respectively, and included IgG, IgA and IgM responses (against receptor binding domain, S1, S2, N), IFN-γ ELISpot as well as neutralisation assays.

Results In patients with RA, IgG responses developed slower with lower peak titres compared with HC. Potent neutralising activity assessed by a SARS-CoV-2 pseudovirus neutralisation assay after 12 weeks was observed in all 21 HCs, and in 60.3% of 73 patients with RA. A significant correlation between peak anti-S IgG levels 2 weeks after the second vaccine dose and potent neutralising activity against SARS-CoV-2 was observed at weeks 12 and 24. The analysis of IgG, IgA and IgM isotype responses to different viral proteins demonstrated a delay in IgG but not in IgA and IgM responses. T cell responses were comparable in HC and patients with RA but declined earlier in patients with RA.

Conclusion In patients with RA, vaccine-induced IgG antibody levels were diminished, while IgA and IgM responses persisted, indicating a delayed isotype switch. Anti-S IgG levels 2 weeks after the second vaccine dose correlate with the development of a potent neutralising activity after 12 and 24 weeks and may allow to identify patients who might benefit from additional vaccine doses or prophylactic regimen.

INTRODUCTION

The development of safe and effective COVID-19 vaccines has been a milestone in controlling the pandemic.1,2 While longitudinal studies in SARS-CoV-2 convalescent and vaccinated individuals have revealed the dynamics of humoral and cellular immune responses in healthy individuals, data on long-term vaccine-induced immune responses in...
patients with rheumatic diseases are still scarce.\textsuperscript{3-5} Two doses of mRNA-based anti-SARS-CoV-2 vaccines result in durable SARS-CoV-2 antibody binding that correlate to potent neutralisation responses in healthy volunteers.\textsuperscript{5,7} Most patients with rheumatic diseases seroconvert following mRNA vaccination but anti-S titres may develop with a delayed kinetic and lower magnitude compared with healthy controls (HCs) depending on the immunomodulatory therapies used.\textsuperscript{8-10}

Lower anti-S levels in patients on immunomodulatory therapies may translate into a lower level of protection. The observation that vaccine effectiveness for prevention of symptomatic COVID-19 in immunosuppressed patients is significantly lower compared with immune-competent controls supports this hypothesis.\textsuperscript{11,12} Immunomodulatory therapies may reduce or prevent antibody responses following SARS-CoV-2 vaccination. In patients with rheumatoid arthritis (RA), the use of JAK inhibitors (tsDMARDs), abatacept or rituximab has been associated with reduced anti-S responses.\textsuperscript{13-16} Reports on decreasing antibody titres over time and the emergence of variants of concern contribute to the uncertainty about the potency and durability of the vaccine induced protection in immunocompromised patients.\textsuperscript{17-19} Efforts seem warranted to optimise vaccine strategies in immunocompromised patients.

The American College of Rheumatology (ACR) and the updated European League against Rheumatism recommendations support a third mRNA vaccine dose in all patients with autoimmune diseases.\textsuperscript{20,21} Although currently not recommended in daily practice, the determination of vaccine-induced antibody responses may help to guide management in patients who are considered to be at risk for an impaired immune response.

The aim of our study was to assess vaccine-induced immune responses following a two-dose regimen of mRNA-based anti-SARS-CoV-2 vaccines over 24 weeks and to analyse the development of neutralisation activity against SARS-CoV-2 in patients with RA on DMARD therapies compared with HCs.

Methods

Study participants

The RECOVER trial (Rheumatoid COVID-19 Vaccine Immune Response) is a non-randomised, prospective, observational, monocentric control group trial. The vaccination itself was not part of the study and performed according to Swiss federal regulations. Consecutive patients with RA on DMARD therapy willing to undergo vaccination were included in our trial. HC mainly consisted of healthcare workers. All participants provided written informed consent before enrolment.

Blood sampling was performed at six study visits: baseline (T0; before first vaccine dose), 3 (T1), 6 (T2, 2 weeks after the second vaccination), 12 (T3) and 24 (T4) weeks after the first vaccine dose. Demographics, medication and clinical data were recorded at all time points.

Serological testing and neutralisation assays

Antibodies to the receptor binding domain (RBD) within the SARS-CoV-2 S1 protein (S) were measured with the Roche Elecsys Anti-SARS-CoV-2-S IgG assay (range 0.4–2500 U/mL, cut-off >0.8 U/mL) and to SARS-CoV-2 nucleocapsid (N) to exclude patients with previously unnoticed COVID-19 infection.

The multiplex bead assay ABCORA was used to measure IgG, IgA and IgM reactivity to four SARS-CoV-2 antigens (RBD, spike glycoprotein subunits S1 and S2, and nucleocapsid protein (N)) as described elsewhere.\textsuperscript{22} In brief, EDTA plasma is diluted (1/100) and incubated with antigen-loaded MagPlex beads (Luminex Corporation, Austin, Texas, USA). To detect bound immunoglobulins (Ig), secondary phycoerythrin-labelled detector antibodies for IgG, IgA or IgM were used and median fluorescence intensity of the single dilution measurements was corrected for background binding (fold over empty beads). To distinguish SARS-CoV-2-specific from cross-reactive antibodies, signal over cut-off (SOC) values were defined for each of the 12 SARS-CoV-2 antigen and Ig class combinations. Results are presented as the sum of SOC values of IgG, IgA and IgM.

Antibody-mediated neutralisation at week 12 was assessed against Wuhan-Hu-1 pseudovirus (HIV-based) as described.\textsuperscript{23} Particles of the env-inactivated HIV-1 reporter construct pHIV-1NL4-3 ΔEnv-NanoLuc (pHIV-1Nanocul; provided by P. Bieniasz, Rockefeller University, New York, USA) were pseudotyped with codon optimised, truncated SARS-CoV-2 spike expression plasmid (p_COV2_Wuhan) by co-expression in 293 T cells. Infection of human ACE2 stable HeLa cells (Biogene, Shirley, New York, USA) with SARS-CoV-2 pseudoparticles was detected by measuring the NanoLuc luciferase reporter activity in cell lysates 48 hours post infection using the Nano-Glo Luciferase Assay System (Promega, Fitchburg, Wisconsin, USA) on a Perkin Elmer EnVision reader. Neutralisation tests of diluted plasma were performed and neutralisation titres causing 50% reduction in viral infectivity (NT50) compared with controls without plasma were calculated using GraphPad Prism with constraints (bottom=0, top=100). If 50% inhibition was not achieved at the lowest plasma dilution of 1/100, a ‘<100’ value was recorded. All measurements were conducted as single measurements.

T cell responses

IFN-γ ELISpots detecting SARS-CoV-2 Spike glycoprotein-reactive T cells after in vitro stimulation with a spike glycoprotein peptide mix were performed as described elsewhere (detailed in online supplemental file 1).\textsuperscript{24}

Statistical analysis

Baseline demographics and laboratory parameters were analysed using descriptive statistics. Comparisons of serological response between patients and controls and between different treatment groups were performed by the Wilcoxon paired samples test and Mann-Whitney test for unpaired samples. $\chi^2$ test was applied for the
comparison of frequencies. Tests were two-sided and done at the 0.05 significance level. Statistical analyses were performed in R (V.4.0.5). Figures were made using the ggplot2 package. Spearman’s correlation test was used to detect associations between continuous variables using GraphPad Prism V.9.0. Receiver operating characteristic (ROC) curve analysis was performed to assess predictability and results expressed as area under the curve (AUC). Comparisons of antigen-specific T cells were performed using GraphPad Prism V.9.0, using repeated measures two-way ANOVAs with Fisher’s LSD multiple comparison test.

RESULTS

Cohort characteristics

Seventy-seven patients with RA on DMARD therapy and 21 HCs were enrolled. Participants with clinically suspected or confirmed previous COVID-19 infection and patients with RA treated with rituximab were excluded.

Baseline characteristics of patients and HC are summarised in table 1. Patients with RA were older than HC (mean age 64±12.5 vs 44.1±13.8 years, p<0.0001). At baseline, 22 of 77 (28.6%) patients with RA received monotherapy with conventional (cs) DMARDs, the majority of them with methotrexate (MTX) (15/22, 68.2%) with a median weekly dose of 15 mg (10–20) or leflunomide (6/22). Thirty-five of 77 (45.5%) patients with RA received biological (b)DMARDs (19 TNF inhibitors, 5 IL-6 receptor inhibitors, 10 abatacept, 1 anakinra), 14 (40%) as monotherapy. JAK inhibitors (tsDMARDs) were used in 20/77 (26%) patients, in 8 (40%) as monotherapy. Medication was continued throughout the vaccination period. Four (5.2%) patients with RA had antibodies to nucleoprotein at

### Table 1 Baseline characteristics, vaccination type and schedule of patients with RA and healthy controls (HCs)

<table>
<thead>
<tr>
<th></th>
<th>Patients with RA (n=77)</th>
<th>Healthy controls (n=21)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (±SD)</td>
<td>64 (12.5)</td>
<td>44.1 (13.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>46 (59.7)</td>
<td>15 (71.4)</td>
<td>0.45 (NS)</td>
</tr>
<tr>
<td>Vaccination type/schedule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA-1273, n (%)</td>
<td>12 (15.6)</td>
<td>0 (0)</td>
<td>0.06</td>
</tr>
<tr>
<td>BNT162b2, n (%)</td>
<td>65 (84.4)</td>
<td>21 (100)</td>
<td></td>
</tr>
<tr>
<td>Mean interval between 1st vaccination and sampling (days±SD)</td>
<td>21.4±2.3</td>
<td>21.8±2</td>
<td>0.33 (NS)</td>
</tr>
<tr>
<td>Mean interval between 2nd vaccination and sampling (days±SD)</td>
<td>14.9±2.5</td>
<td>15.1±1.6</td>
<td>0.22 (NS)</td>
</tr>
<tr>
<td>Mean interval between 1st and 2nd vaccination (days±SD)</td>
<td>34.5±4</td>
<td>32.9±5.9</td>
<td>0.15 (NS)</td>
</tr>
<tr>
<td>RA disease characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACPA+RF, n (%)</td>
<td>48/77 (62.3)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>ACPA+RF+, n (%)</td>
<td>37/77 (48.1)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>ACPA+, n (%)</td>
<td>38/77 (49.4)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>RF+, n (%)</td>
<td>47/77 (61.0)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Disease activity (CDAI) at baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remission (≤2.8), n (%)</td>
<td>17/77 (22.1)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Low disease activity (2.9–10), n (%)</td>
<td>40/77 (51.9)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Moderate disease activity (10.1–22.0), n (%)</td>
<td>15/77 (19.5)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>High disease activity (≥22.1), n (%)</td>
<td>5/77 (6.5)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>DMARD therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARDs-mono, n (%)</td>
<td>22/77 (28.6)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>bDMARDs-mono/combo, n (%)</td>
<td>35/77 (45.5)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>bDMARDs-mono, n (%)</td>
<td>14/35 (40)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>tsDMARDs-mono/combo, n (%)</td>
<td>20/77 (26)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>tsDMARDs-mono, n (%)</td>
<td>8/20 (40)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Prednisone, n (%)</td>
<td>25/77 (32.5)</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Mean daily dose prednisone (mg±SD)</td>
<td>5.6±3.6</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as n (%) or mean as indicated. Anti-cytokine bDMARDs and abatacept are summarised as bDMARDs. Targeted synthetic (ts)DMARDs included tofacitinib, baricitinib and upadacitinib.

RA, rheumatoid arthritis.
baseline in line with a clinically unnoticed COVID-19 infection and were excluded from the immunogenicity analyses. After 12 weeks, three patients with absent anti-S antibodies received a third vaccine dose, one of these patients had underlying RA-ILD, developed COVID-19 3 months after the third dose and died. Two patients declined further participation. Sixty-eight of the remaining 72 (93.2%) patients were followed until week 24 after vaccination.

RA disease activity was prospectively assessed using CDAI until week 12. At baseline, 17/77 (22.1%) and 40/77 (51.9%) patients with RA were in remission or low disease activity. Significant increases in CDAI were noted after the first and second vaccination (p<0.0001) and after 12 weeks (p<0.001), and RA treatment was modified in 11/77 (14.3%) patients with RA (online supplemental figure 1).

**Anti-S IgG responses to mRNA SARS-CoV-2 vaccine**

We longitudinally assessed the antibody response to SARS-CoV-2 S antigen detected by the Elecsys Anti-SARS-CoV-2 assay (anti-S) in patients with RA and HC. The majority of patients with RA (92%) seroconverted 12 weeks after the first vaccine dose (T3), nine patients did not mount a response even after two doses. Anti-S levels were significantly lower in patients with RA compared with HC at all time points after two vaccine doses (T2, T3, T4) (figure 1A, online supplemental figure 2). Anti-S levels of patients with RA treated with csDMARD-mono versus anti-cytokine bDMARDs-mono/combo were comparable at week 12. At week 24, patients receiving anti-cytokine bDMARDs-mono/combo showed significantly lower anti-S levels compared with patients on csDMARD-mono (median 94 (37–218) vs 388 (165–734) U/mL), p=0.02. Patients using anti-cytokine bDMARDs-mono had numerically higher anti-S levels (median 152 (42–507) U/mL) compared with patients on anti-cytokine bDMARDs-combo (median 70 (28–192) U/mL).

Patients treated with abatacept showed numerically lower anti-S levels at week 12 compared with patients with csDMARD-mono (median 158 (41–498) vs 782 (176–1216) U/mL), p=0.08, and significantly lower levels at week 24 (median 66 (21–94) vs 388 (165–734) U/mL), p<0.01. In patients on tsDMARDs, anti-S levels were significantly lower compared with patients on csDMARD-mono at 12 and 24 weeks (median 132 (29–542) and 64 (18–224) vs 782 (176–1216) and 388 (165–734) U/mL), p<0.05 and p<0.01, respectively.

There was no association between disease activity as monitored by CDAI or seropositivity and anti-S levels at any timepoint. As the mean age of patients with RA was higher compared with HC, we matched patients with RA with HCs regarding age and type of vaccination. Patients with RA revealed significantly lower anti-S levels at all timepoints following vaccination whereas T cell responses did not differ (online supplemental figure 3A,B).

**Neutralising activity against SARS-CoV-2**

The neutralising potency of the measured antibody response is a critical correlate of protective immunity after vaccination. We measured the neutralising activity in patients with RA and HCs using a pseudovirus-neutralisation assay against Wuhan-Hu-1 at week 12. All HCs developed high neutralisation titres compared with patients with RA. 39.7% of patients with RA did not mount a potent neutralising response (NT50≤250) (p=0.0003) and the absence of neutralising activity at week 12 (NT50≤100) was noted in 23.3% patients with RA. The absence of neutralising activity was noted more frequently in patients with RA on abatacept or tsDMARDs, compared with patients with RA on csDMARDs-mono or anti-cytokine bDMARDs-mono/combo (figure 1B).

Seroprophiling with the ABCORA assay allows to predict whether infected individuals develop high (NT50≤250) or low neutralisation titres (NT50≤250), respectively, by the sum of S1 signal over cut-off (SOC) values for IgG, IgA, IgM (sum S1) against different viral antigens. The sum S1 threshold of 17.3 reliably predicts neutralisation activity against the vaccine strain Wuhan-Hu-1 with a specificity of 94% and a sensitivity of 67%. All HCs in our study exceeded the sum S1 predicting potent neutralisation at all timepoints following two vaccination doses. In contrast, patients with RA had significantly lower sum S1 levels at all timepoints (figure 1C).

**Postvaccination anti-S levels predict neutralising activity after 12 and 24 weeks**

A strong correlation between anti-S antibody levels 2 weeks after the second vaccine dose and a potent neutralising activity (NT50) at week 12 was observed. Patients with RA with NT50≥250 at week 12 had significantly higher anti-S levels 2 weeks after the second vaccine dose compared with patients with RA with low or absent neutralising activity (median 1769 (634–2500) vs 131 (0.4–409) and 0.65 (0–129), p<0.0001 and p=0.0001, respectively) (figure 2A). We confirmed the correlation between peak anti-S levels after the second vaccine dose (T2) and NT50 at 12 weeks (T3) by using the spearman correlation coefficient (r=0.5506) and linear regression (F=69.99), p<0.0001. A ROC curve with an AUC (AUC=0.8726, 95% CI 0.80 to 0.95), p<0.0001, revealed a decisive anti-S threshold of 937 U/mL (figure 2B).

Sum S1 levels as determined by the ABCORA assay allow to predict neutralising responses by measuring isotype responses to four different viral antigens. Peak anti-S IgG antibody levels correlated to neutralising responses as predicted by ABCORA (sum S1) at week 12 (T3) (r=0.78 (CI 0.67 to 0.86), p<0.0001) and week 24 (T4) (r=0.67 (CI 0.50 to 0.79), p<0.0001) (figure 2C,D).

**Analysis of SARS-specific IgG, IgA and IgM isotype responses**

The longitudinal analysis of isotype responses against four SARS-CoV-2 antigens (RBD1, S1, S2 and N) using the ABCORA assay allows to differentiate partial (only IgA and IgM responses) and full seroconversion (including
IgG responses). Our analysis revealed a differential dynamic of the humoral response between patients with RA and HC (figure 3A). IgG responses to S1 and RBD that show the highest correlation with neutralising activity developed in patients with RA with a slower kinetic and lower magnitude while IgA responses tended to persist (figure 3A). IgM antibodies directed against RBD and S1 persisted longer in patients with RA compared with HC (figure 3B). These data suggest a delayed isotype switch in patients with RA following anti-SARS-CoV-2 vaccination that may underlie the delay in the development of strong IgG responses.

**SARS-CoV-2 specific IFN-γ release**

The number of IFN-γ-spot forming cells (s.f.c) was comparable between HC and patients with RA, with a peak 2 weeks after the second vaccine dose (T2) and decrease thereafter. In patients with RA, a more rapid decline was noted at week 24 compared with HC (online supplemental figure 4). No significant differences regarding the T cell
response between patients with RA on csDMARD-mono, anti-cytokine bDMARDs-mono/combo or tsDMARDs were detected. Results are described in detail in online supplemental file 1.

DISCUSSION

The successful development of vaccines for COVID-19 has altered the course and severity of the pandemic, but vaccine efficacy against SARS-CoV-2 variants may lag behind the spread of new variants and anti-S antibodies may wane over time. The importance of a robust humoral immune response is supported by the clinical efficacy of therapeutic and prophylactic antibodies against the spike protein and studies confirmed a reduced occurrence of COVID-19 infections in participants with higher vaccine-induced anti-S or RBD IgG antibodies correlating with higher pseudovirus neutralisation titres. Breakthrough SARS-CoV-2 infections in fully vaccinated patients with rheumatic diseases resulting in severe disease courses have been reported. Optimising vaccine strategies is therefore of interest in this patient population.

The ACR has recommended a third mRNA vaccine dose to patients with rheumatic diseases, that may be applied at least 28 days after the second dose of the primary vaccination series. The optimal timepoint and threshold levels of vaccine-induced immune responses have not yet been determined. The determination of anti-S antibody levels given their correlation to neutralisation therefore represents an attractive option in immunocompromised patients to monitor vaccine effectiveness and guide clinical management.

In this prospective, longitudinal study, patients with RA showed significantly lower anti-S titres at all timepoints
than HC. While patients with RA using anti-cytokine bDMARDs in monotherapy showed anti-S levels comparable to those of patients on csDMARD monotherapy after 12 and 24 weeks, we observed lower anti-S levels in patients on tsDMARDs, abatacept or anti-cytokine bDMARDs in combination with csDMARDs as reported by others.33–35 Potent neutralising responses as determined by an HIV-based pseudovirus system (NT50) and the multiplex ABCORA assay were detected in all HC but were absent in a large proportion of patients with RA. Of note, we observed a significant correlation between anti-S responses 2 weeks after the second vaccine dose and the development of potent neutralisation activity as assessed by NT50 after 12 weeks and ABCORA after 12 and 24 weeks. The early determination of anti-S titres 2 weeks after the second vaccine dose may thus allow to identify patients with RA with a higher likelihood of low or absent neutralising antibodies thereafter who would benefit from an earlier third vaccine dose.

Patients with RA demonstrated significantly impaired neutralising responses as assessed by ABCORA at all time-points following a standard vaccination regimen. Of note, IgG responses to spike antigens show the highest correlation with neutralisation activity.22 The development of a robust IgG response to S1, S2 and RBD was significantly delayed in patients with RA compared with HC. Our findings suggest a delayed isotype switch in vaccine-induced antibody development in patients with RA that might, at least in part, explain these findings. Further studies are needed to corroborate whether the delayed development of a vaccine-induced IgG response is mitigated by the use of certain DMARDs which were continued throughout the vaccination period in our study or whether temporary interruption of DMARDs may promote the rapid development of IgG responses.36 37

Figure 3 Longitudinal vaccine-induced antibody responses by isotypes of vaccinated RA patients compared to healthy controls. (A) Comparison of IgA and IgG responses in RA patients capable of mounting an immune response after vaccination (n=64) and HC at visits T1 and T2. Levels of significance are calculated by unpaired t-test. *p<0.05, **p<0.01, ***p<0.001. (B) Heatmaps summarizing the measured MFI signals normalized to empty bead control (MFI FOE) that visualize IgG, IgA and IgM responses to RBD, S1, S2 and N on different DMARD regimen after the first (T1) and second vaccine dose (T2) and after 12 (T3) and 24 weeks (T4) for HC and RA patients. T1=3 weeks after 1st vaccination, T2=2 weeks after 2nd vaccination, T3=12 weeks after 1st vaccination, T4= 24 weeks after 1st vaccination *p<0.05, **p<0.01, ***p<0.001.
may include a timely additional vaccine dose, an interruption of DMARD therapy or the use of pre-exposure monoclonal antibodies.

**Author affiliations**

1 Division of Rheumatology and Immunology, Kantonsspital St Gallen, Sankt Gallen, Switzerland
2 Institute of Medical Virology, University of Zurich, Zurich, Switzerland
3 Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Zurich, Switzerland
4 Institute of Immunobiology, Kantonsspital St Gallen, Sankt Gallen, Switzerland
5 Laboratory Medicine Division, University of Geneva, Geneve, Switzerland
6 Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

**Acknowledgements** We are grateful to all volunteers and patients for their participation, and we thank all involved study coordinators and nurses for their contribution. We also thank all involved technicians and lab personnel for their work.

**Contributors** All authors have made substantial contributions to the conception, design of the study, or the acquisition, analysis and interpretation of the data, were involved in drafting the manuscript or critical revision. All authors approved the final version of the manuscript. The authors assume responsibility for the accuracy of the data and analyses and the fidelity of the trial.

**Funding** The study was supported by internal institutional grants of the investigators including a Pandemiefond UZH foundation (AT) and a Swiss national Science Foundation Grant (NBP).

**Competing interests** ARR received consulting fees from Abbvie, Gilead, Lilly, BMS and Sanofi, honoraria from Abbvie, Pfizer, Sanofi, UCS, BMS, Lilly, Gilead and Roche, payment for expert testimony from Abbvie and Gilead, support for travel or meeting attendance from Sanofi, Roche and Abbvie and compensation for participation on a Data Safety Monitoring Board from R Pharm, outside the submitted work. KS reports support for travel or meeting attendance from Abbvie, BMS, Pfizer and Sanofi, honoraria from Lilly and support for travel or meeting attendance from Pfizer outside the submitted work. AT received a research grant from the Gilead foundation, and consulting fees from Roche and Neuroimmun. All other authors declare no competing interests.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** This study involves human participants. The study was approved by the Cantonal Ethical Committee of St. Gallen, Switzerland (BASEC 2021-00156). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**ORCID iD**

Andrea Rubbert-Roth http://orcid.org/0000-0002-9016-2833

**REFERENCES**

Rheumatoid arthritis


